[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radio-potentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [131I]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [131I]MIBG in vitro.
McCluskey
Anthony G
AG
Targeted Therapy Group & Department of Child Health, Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Glasgow G61 1BD, UK. t.mccluskey@beatson.gla.ac.uk
Boyd
Marie
M
Gaze
Mark N
MN
Mairs
Robert J
RJ
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004249:DNA Damage; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D019275:Radiopharmaceuticals; D059004:Topoisomerase I Inhibitors; D019797:3-Iodobenzylguanidine; D019772:Topotecan